See the Complete Picture.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eurovision
Pope Leo XIV
Cannes Film Festival
IPL
Premier League
Pope Francis
South America
Soccer
Social Media
European Union
Formula 1
Natural Disasters
Published • loading... • Updated

Capecitabine/Bevacizumab Yields Antitumor Activity and a Favorable Safety Profile in Older mCRC Population

Summary by onclive.com
Capecitabine/bevacizumab had favorable efficacy and safety profiles among older patients with metastatic colorectal cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
oncnursingnews.comoncnursingnews.com

Bevacizumab Combo Appears Effective, Safe for Older Patients With mCRC

The addition of bevacizumab to capecitabine produced favorable efficacy and safety data for older patients with metastatic colorectal cancer.

Read Full Article
onclive.comonclive.com

Capecitabine/Bevacizumab Yields Antitumor Activity and a Favorable Safety Profile in Older mCRC Population

Capecitabine/bevacizumab had favorable efficacy and safety profiles among older patients with metastatic colorectal cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

onclive.com broke the news in on Tuesday, May 13, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Cancer

Cancer

News
For You
SearchBlindspotLocal